Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $36.84 and last traded at $36.0160, with a volume of 3075248 shares. The stock had previously closed at $22.75.
Analysts Set New Price Targets
A number of brokerages recently commented on KOD. HC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of Kodiak Sciences in a research note on Tuesday, February 10th. UBS Group assumed coverage on shares of Kodiak Sciences in a research report on Wednesday, January 7th. They set a "buy" rating and a $50.00 price objective for the company. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $28.29.
Get Our Latest Analysis on Kodiak Sciences
Kodiak Sciences Trading Up 62.7%
The stock has a market cap of $1.96 billion, a P/E ratio of -8.99 and a beta of 2.61. The firm has a 50-day simple moving average of $24.69 and a two-hundred day simple moving average of $21.49.
Institutional Trading of Kodiak Sciences
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Boone Capital Management LLC acquired a new position in shares of Kodiak Sciences during the 3rd quarter worth approximately $11,719,000. TD Asset Management Inc acquired a new stake in shares of Kodiak Sciences in the third quarter valued at approximately $992,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Kodiak Sciences in the third quarter valued at approximately $488,000. Panagora Asset Management Inc. boosted its stake in shares of Kodiak Sciences by 28.5% in the second quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company's stock valued at $489,000 after buying an additional 29,113 shares during the period. Finally, Vanguard Group Inc. grew its position in Kodiak Sciences by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 2,313,395 shares of the company's stock worth $64,683,000 after buying an additional 363,103 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
